Skip to main content
. 2021 Jun 21;13(12):3101. doi: 10.3390/cancers13123101

Figure 4.

Figure 4

Comparison between groups of patients with high (≥1%) versus low/undetectable (<1%) baseline MAF for PFS. Kaplan–Meier curve for PFS according to MAF levels at baseline (pretreatment)—high versus low/undetectable. PFS: progression-free survival; MAF: mutant allele frequency.